OBJECTIVE： To investigate the clinical efficacy and safety of Xuebijing injection in adjunctive therapy of severe acute pancreatitis （SAP）. METHODS： 90 patients with SAP were selected and divided into control group and observation group according to random number table， with 45 cases in each group. Control group was given routine treatment as nutritional support， detaining gastric tube， antibiotics， continuous blood perfusion， etc. Observation group was additionally given Xuebijing injection 100 ml，bid， on the basis of control group. Both group received treatment for 7 d. The improvement time of blood amylase， abdominal pain， body temperature， abdominal distension， nausea and vomiting， and white blood cells， the incidence of complications， clinical efficacy as well as the occurrence of ADR were compare between 2 groups. RESULTS： The improvement time of blood amylase， abdominal pain， body temperature， abdominal distension， nausea and vomiting， white blood cells in observation group were significantly shorter than in control group； the incidence of compliance was significantly lower than control group（17.78％ vs. 64.44％）， while total effective rate was significantly higher than control group（91.11％ vs. 73.33％）， with statistical significance （P＜0.05）. 2 patients suffered from headache and nausea in observation group， and no obvious ADR was found in control group. CONCLUSIONS： Xuebijing injection is effective for adjunctive therapy of SAP with good safety； the patients recover quickly and the incidence of complications was in low level.